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AbstrAct
Introduction Despite advances in infection prevention 
and control, catheter-associated urinary tract infections 
(CAUTIs) are common and remain problematic. A number 
of measures can be taken to reduce the risk of CAUTI 
in hospitals. Appropriate urinary catheter insertion 
procedures are one such method. Reducing bacterial 
colonisation around the meatal or urethral area has 
the potential to reduce CAUTI risk. However, evidence 
about the best antiseptic solutions for meatal cleaning 
is mixed, resulting in conflicting recommendations 
in guidelines internationally. This paper presents the 
protocol for a study to evaluate the effectiveness 
(objective 1) and cost-effectiveness (objective 2) of 
using chlorhexidine in meatal cleaning prior to catheter 
insertion, in reducing catheter-associated asymptomatic 
bacteriuria and CAUTI.
Methods and analysis A stepped wedge randomised 
controlled trial will be undertaken in three large Australian 
hospitals over a 32-week period. The intervention in 
this study is the use of chlorhexidine (0.1%) solution for 
meatal cleaning prior to catheter insertion. During the 
first 8 weeks of the study, no hospital will receive the 
intervention. After 8 weeks, one hospital will cross over to 
the intervention with the other two participating hospitals 
crossing over to the intervention at 8-week intervals 
respectively based on randomisation. All sites complete 
the trial at the same time in 2018. The primary outcomes 
for objective 1 (effectiveness) are the number of cases of 
CAUTI and catheter-associated asymptomatic bacteriuria 
per 100 catheter days will be analysed separately using 
Poisson regression. The primary outcome for objective 
2 (cost-effectiveness) is the changes in costs relative to 
health benefits (incremental cost-effectiveness ratio) from 
adoption of the intervention.
Dissemination Results will be disseminated via 
peer-reviewed journals and presentations at relevant 
conferences.A dissemination plan it being developed. 
Results will be published in the peer review literature, 
presented at relevant conferences and communicated via 
professional networks.
Ethics Ethics approval has been obtained.
trial registration number 12617000373370, approved 
13/03/2017. Protocol version 1.1.
IntroDuctIon
Indwelling urinary catheters are commonly 
used in healthcare facilities, with founda-
tion work indicating that 26% of patients 
admitted to an Australian hospital receive an 
indwelling urinary catheter and 1% of these 
patients develop catheter-associated urinary 
tract infections (CAUTIs).1CAUTIs have 
been associated with increased morbidity, 
mortality, increased length of stay in hospital 
and higher hospital costs for patients and 
health systems.2 Data from the International 
Nosocomial Infection Control Consortium 
(INICC) surveillance study, conducted in 703 
intensive care units in low and middle-income 
countries, suggest the incidence of CAUTI 
to be 4.8 per 1000 device days (years 2010–
2015).3 In Australia, an estimated 380 000 bed 
days are lost each year due to healthcare-asso-
ciated urinary tract infections (UTIs), a large 
proportion of which are CAUTIs. CAUTIs are 
also associated with higher risk of antimicro-
bial resistance (AMR), making the treatment 
of patients difficult.4 5AMR in UTIs has also 
been shown to be increasing globally, further 
emphasising the need to develop interven-
tions to reduce the incidence of CAUTIs.6 
Studies have shown that the incidence 
of CAUTI can be reduced.7 8 Nonetheless, 
despite some advances in infection preven-
tion and control, CAUTIs remain prob-
lematic.9 Evidence shows that reducing 
bacterial colonisation around the meatal 
or urethral area has the potential to reduce 
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strengths and limitations of this study
 ► Randomised control design
 ► Evaluation of effectiveness and cost-effectiveness
 ► Limited to hospitals in high-income country
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Figure 1 Study design overview. Blue, control; green, intervention.
CAUTI risk.10 However, evidence about the best anti-
septic solutions for meatal cleaning is mixed. Previous 
research also identified a lack of documentation and 
knowledge in relation to the meatal cleaning solution 
used prior to catheter insertion.1 Unsurprisingly, there 
is variation in practice within Australian hospitals with 
respect to catheter insertion, and specifically the agent 
used to clean the meatal area prior to insertion. These 
issues provided a strong rationale for the study investi-
gators to conduct a systematic review and meta-analysis 
of published literature, investigating the effectiveness 
of antiseptic cleaning during urinary catheter insertion 
for the prevention of CAUTI.11 This review of current 
research knowledge identified the need for a well-de-
signed intervention study as well as a limited number 
of studies evaluating the cost-effectiveness of using an 
antiseptic during catheter insertion. As health budgets 
are finite, clinical practice needs to use cost-effective 
strategies. The cost of chlorhexidine 0.1% solution is 
considerably higher than 0.9% normal saline.
Given the importance of meatal colonisation in the 
pathogenesis of CAUTIs, emerging AMR, the frequency 
with which catheters are used and the burden of CAUTIs 
in Australia and in hospital settings worldwide, the gener-
ation of evidence using a high-quality randomised trial is 
needed to determine the efficacy and cost-effectiveness 
of meatal cleaning. This will inform infection preven-
tion and control practice and policy in Australia and 
internationally.
trial objectives
The trial objectives listed below pertain to both the 
cluster and individual level. The trial is registered with 
the Australia New Zealand Clinical Trial Registry (No 
12617000373370).
Objective 1
The first objective is to evaluate the effectiveness of using 
chlorhexidine in meatal cleaning prior to catheter inser-
tion, in reducing catheter-associated asymptomatic bacte-
riuria (CA-ASB) and CAUTI.
Objective 2
The second objective is to estimate the cost-effectiveness 
of the decision to adopt chlorhexidine in meatal cleaning 
prior to catheter insertion.
MEthoDs
study design
A stepped wedge randomised controlled trial will be 
undertaken in three large hospitals over a 32-week period 
(example trial timing are in figure 1). The stepped wedge 
design includes an initial period where no hospitals are 
exposed to the intervention.12 Afterwards, at 8-week 
intervals (the ‘steps’) each hospital sequentially crosses 
over from the control to the intervention until all hospi-
tals are exposed to the intervention for the final 8 weeks 
until conclusion in week 32. The study design enables 
each hospital to act as its own control, which removes 
the potential for some confounders such as variations 
in hospital size and case mix and differences between 
public and private hospitals. Staggered commencement 
and duration of the intervention supports feasibility while 
maintaining the rigour of the study.13 This design will also 
allow research staff to work with individual hospitals as 
they change over, maximising consistency of intervention 
and aiding implementation.13 In addition, data collec-
tion continues throughout the study, so that each cluster 
contributes observations under both control and inter-
vention observation periods.
study population
Three Australian hospitals that fulfil the eligibility criteria 
will be enrolled in the study. These criteria are as follows:
1. Has an intensive care unit
2. Be classified by the Australian Institute of Health and 
Welfare as a principal referral hospital OR a public 
acute group A hospital (with more than 400 beds), 
OR in the case of a private hospital has 400 inpatient 
beds OR has more than 30 000 patient admissions per 
year.
Other considerations
Hospitals could be excluded from the study if within the 
study time frame they are
1. undertaking a project that may influence the outcomes 
measured in this study
2. opening, closing or relocating.
Areas of hospital and patient-level inclusion and exclusion criteria
The study will be a hospital wide study, but will exclude 
patients with indwelling urinary catheters within a 
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Table 1 Key outcome measures
Objective 1
Effectiveness of using chlorhexidine in 
meatal cleaning prior to catheter insertion
Primary outcome The number of cases of CA-ASB per 100 catheter days
The number of cases of CAUTI per 100 catheter days
Secondary outcome The number of BSIs associated with a UTI
Objective 2
Cost-effectiveness of the intervention
Primary outcome Changes in costs relative to health benefits (incremental 
cost-effectiveness ratio) from adoption of the intervention
Changes in costs associated with implementing the 
intervention relative to the change in QALYs
BSI, blood stream infection; CA-ASB, catheter-associated asymptomatic bacteriuria; CAUTI, catheter-associated urinary tract infection; QALY, 
quality-adjusted life years; UTI, urinary tract infection.
hospital that are not considered appropriate for the inter-
vention, for example neonatal intensive care. Patients 
<2 years old, with an allergy, contraindication or other 
medical reason preventing the use of the intervention 
for cleaning the urethral meatal area will be excluded. 
Patients who require in-and-out or suprapubic catheteri-
sation will also be excluded as well as those with symptoms 
and signs suggestive of UTI and patients already under-
going treatment for UTI. All data from any patient lost to 
follow-up (postcatheter insertion) will be excluded.
recruitment
The study team will list all eligible sites then order the 
list to ensure (1) a representation of both private and 
public hospitals and (2) representation from at least two 
Australian states and territories. The recruitment process 
will purposively select and approach eligible hospitals to 
optimise the feasibility and practicality of completing the 
trial.
Intervention
The intervention in this study is the use of chlorhexi-
dine (0.1%) solution for meatal cleaning prior to cath-
eter insertion. The control is the use of normal saline 
(0.9%) for meatal cleaning. During the first 8 weeks of 
the study, no hospital will receive the intervention. After 
8 weeks, one hospital will cross over to the intervention 
with the other two participating hospitals crossing over to 
the intervention at 8-week intervals respectively based on 
randomisation.
Implementing the intervention
In the week prior to the intervention commencing, infor-
mation sessions about the study will be provided to partic-
ipating hospitals and staff. A variety of methods will be 
used to further alert staff and raise awareness about the 
intervention prior to it being rolled out. These methods 
include placing wall posters in wards and key hospital 
locations, handing out hospital newsletters and infor-
mation leaflets as well as branded promotional material, 
such as pens. To avoid potential confounding, informa-
tion and awareness sessions are limited to just the change 
of product, not education around catheter insertion or 
management practices.
Chlorhexidine 0.1% solution will be used by clinical staff 
at participating hospitals for cleaning the meatal area of 
patients prior to urinary catheter insertion. To aid imple-
mentation of the intervention, investigators will work with 
participating hospitals and use hospital data collection 
and reporting systems currently in place. This will involve 
incorporation of the 0.1% chlorhexidine solution into 
existing catheter procedure packs at the hospitals where 
possible, visual reminders where urinary catheters are 
stored and temporary amendment to hospital procedural 
documentation.
As per hospital’s usual practice, details of the catheter 
insertion will be documented by clinical staff. To achieve 
optimal documentation of the procedure, catheter inser-
tion stickers may be made available to hospitals for use in 
patients’ medical notes.
Potential confounders
Lubricants are used during the catheter insertion process 
and may contain an antiseptic. The lubricant used during 
the entire study (control and intervention periods) will 
remain constant in each hospital.
randomisation and blinding
Hospitals will be randomly assigned to one of three dates 
to cross over to the intervention which will occur once 
every 8 weeks over the trial duration of 32 weeks. All 
included hospitals will be provided with sufficient notice 
of the dates to cross over to the intervention. Comput-
er-generated randomisation of the cross over dates for the 
hospitals will be performed independently by an investi-
gator not involved in assessment or delivery of the inter-
vention. Hospitals will not be blinded because it is not 
feasible to blind staff administering the intervention. The 
outcome of the randomisation process will be revealed by 
the project manager to the participating hospitals prior 
to the commencement of the study.
outcomes and definitions
The outcomes for each objective are outlined in table 1. 
For objective 1, the primary outcomes are the cases of 
CA-ASB and CAUTI. For objective 2, the primary outcome 
is the cost-effectiveness of the intervention.
Catheter-associated asymptomatic bacteriuria is defined 
as the presence of ≥105 colony-forming unit (cfu)/ml 
of ≥1 bacterial species in a single catheter urine specimen 
in a patient without symptoms compatible with UTI.14
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Figure 2 Overview of data collection process.
Catheter-associated urinary tract infection is defined 
according to the National Healthcare Safety Network 
criteria.15 16 A patient must meet all three criteria below:
1. Patient had an indwelling urinary catheter that had 
been in place for >2 days on the date of event (day of 
device placement=day 1) AND was either present for 
any portion of the calendar day on the date of event 
or removed the day before the date of event.
2. Patient has at least one of the following signs or symp-
toms: fever (>38.0°C); suprapubic tenderness; costo-
vertebral angle pain or tenderness; urinary urgency; 
urinary frequency; dysuria.
3. Patient has a urine culture with no more than two 
species of organisms identified, at least one of which 
is a bacterium of ≥105 cfu/mL.
Blood stream infection (BSI) associated with a UTI is 
defined according to National Healthcare Safety Network 
criteria.15 A patient must meet the definition for CAUTI 
and has at least one organism from the blood specimen 
that matches an organism identified in the urine spec-
imen that is used as an element to meet the CAUTI crite-
rion. The blood specimen must be collected during the 
secondary BSI attribution period when the urinary cath-
eter is in place.
Data collection
Data will be collected by a specific staff member or 
members at the hospital, with the support of the research 
team. The research team will provide the hospital staff 
member(s) with training about the project, data collec-
tion and submission process and data collection tools. 
For the purpose this paper, the dedicated hospital staff 
member(s) will be referred to as hospital personnel. 
Figure 2 summarises the data collection process.
Hospital personnel will prospectively collect data 3 days 
a week at each hospital during both control and interven-
tion periods. Patients who receive an indwelling urinary 
catheter will be identified and followed-up during the 
trial period (for a period of 7 days postcatheter insertion, 
discharge or 48 hours postcatheter removal—whichever 
occurs first). Medical notes of patients will be reviewed 
to obtain demographic and clinical data such as hospital 
number, age, sex, date of admission, signs or symptoms of 
UTI. Co-morbidity data will be collected where possible.
Details of catheter insertion specifically date and time of 
insertion, designation of person inserting catheter, cath-
eter type and catheter size will also be obtained from the 
patients’ medical notes (where documented). If the inser-
tion date is not documented, the patient will be excluded 
from the study. Denominator data on the number of cath-
eter days over the trial period will be collected at each 
hospital during both control and intervention periods. 
The number of catheter days for each patient included in 
the study will be estimated from the date of catheter inser-
tion and date of removal. Hospital personnel will record 
all captured data in a spreadsheet designed specifically 
for the purpose of the trial.
Information for the primary (CA-ASB and CAUTI) 
and secondary (BSI) outcome measures will be collected 
from the microbiology laboratory database of partici-
pating hospitals. Results of all positive urine cultures 
either attributable to bacteriuria or true UTI as well as 
positive blood cultures are registered in hospital micro-
biology laboratory databases. Hospital personnel will 
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obtain weekly reports from the microbiology laboratory 
of participating hospitals to identify the outcomes. The 
patient record number will be used to link demographic 
and clinical data of patients with a urinary catheter to 
microbiology laboratory data. To differentiate between 
CA-ASB and CAUTI, additional data on symptoms and 
signs of UTI will be collected from patients’ medical 
notes by research assistants.
Information to inform changes to total costs and health 
benefits from a decision to adopt the intervention will 
be obtained. Changes to costs will include the resources 
required to implement the intervention and the changes 
to use of health services. Changes to health benefits 
will be captured by estimating quality-adjusted life years 
(QALY) outcomes. Hospital personnel will prospectively 
obtain monthly data from each participating hospital on 
the cost of purchasing resources, such as catheter proce-
dure packs, used for implementing the intervention. 
Hospital personnel will also obtain data on antimicrobial 
use for patients, specifically the name, dose and dura-
tion of antimicrobial, which will be used for estimating 
antimicrobial therapy costs in control and intervention 
periods. Hospital staff involved in the trial will be surveyed 
immediately following completion of the intervention 
to evaluate extra staff time spent in activities related to 
planning and implementing the intervention. To calcu-
late QALYs, primary data on age obtained from medical 
notes of patients will be used along with estimates from 
the published literature.17
Power calculation
Sample size and power were calculated on the basis of 
CAUTI, as it is assumed that the power to detect an incre-
mental cost-effectiveness ratio was greater than that for 
relevant clinical endpoints. The at-risk population are 
those that receive a catheter while in hospital. Based on 
pilot work, the estimated proportion of patients devel-
oping a CAUTI for this study is 3.4%.1 We estimate a 
20% reduction using a Cohen’s d size effect measure 
at 0.2 (small effect). Based on individual randomisa-
tion of two groups (control and intervention), power of 
80%, alpha of 0.05%, effect size of 0.2 and two-sided test 
for comparison of two means were estimated. As this 
is a stepped wedge design, we have used a sample size 
formula from Hussey and Hughes and operationalised 
the design effect from Hemming.12 18 For the design 
effect, we have assumed three hospitals, three time 
periods, with N1 being the sample size of 784. Three 
different scenarios were modelled, each with different 
intracluster correlation coefficients—0.1, 0.05, 0.01. 
An intracluster correlation coefficient of 0.05 was 
subsequently determined and the sample size (m=220, 
M=880) for each cluster.
Pilot work identified that 26% of patients admitted to 
hospital in Australia receive a urinary catheter.1 19 As we 
are excluding patients who had a catheter inserted in 
theatre, we estimated that 5% of admitted patients receive 
a catheter not inserted in theatre. To obtain the required 
sample size in each hospital, a hospital is to have at least 
30 000 patient admissions per year.
Analysis
Objective 1: effectiveness of using chlorhexidine in meatal cleaning 
prior to catheter insertion
The number of CA-ASB, CAUTI and BSI will be analysed 
separately using Poisson regression, with the number of 
cases as the dependent variable and number of patient 
catheter days as the denominator. This denominator will 
help control for changes in catheter use during the study 
period. The key independent variable will be the inter-
vention. The key outcomes will be estimated reduction 
in cases of CA-ASB, CAUTI and BSI due to the interven-
tion. The characteristics of the hospital (eg, size) will not 
be independent variables as these should remain roughly 
constant throughout the study observations. There is 
no expected delay in the effect of intervention on the 
outcome.
Objective 2: cost-effectiveness of the intervention
The effectiveness data from objective 1 will be a key 
parameter in the cost-effectiveness model. Final outcomes 
for the cost-effectiveness evaluation are the incremental 
cost-effectiveness ratio estimated as the cost per QALY 
gained, and the changes to costs in QALYs. Published 
guidelines for costing an intervention will be followed.20 
The changes to costs from adopting the intervention 
will be estimated by the extra staff time spent both plan-
ning and implementing the intervention, converted to a 
dollar figure using full employment costs. Other costs are 
product costs. These cost data will be collected prospec-
tively on a monthly basis for product costs and a survey 
immediately after the intervention is implemented (staff 
costs). Quantities of resources will be standardised to 
all hospitals to ensure valid comparison of costs across 
all sites. This will reduce uncertainty in estimates which 
often results from using retrospective administrative data.
The major cost savings from reducing infections are char-
acterised by the bed days saved from keeping patients infec-
tion free and hence discharging them earlier. The reasoning 
is that 90% of the costs of hospital services are fixed so bed 
days saved are an appropriate currency. Data from a previous 
study using multistate modelling to estimate the extra length 
of stay per case of urinary bacteriuria will be used in the 
model.21 Other cost savings are averted laboratory diagnosis 
costs and antimicrobial therapy costs, estimated by counting 
the frequency of laboratory tests and antimicrobial therapy 
costs in the control and intervention periods. These will be 
collected prospectively as part of the data collection process. 
Laboratory costs using the relevant medical benefit scheme 
item costs will be used. For antimicrobial therapy costs, phar-
maceutical benefits scheme costs will be used.
Changes to health benefits will be informed by the extra 
death risk due to infection. This parameter will come from 
a previously described analysis of mortality associated with 
urinary bacteriuria. These estimates used multistate models 
that avoid time and length biases to estimate increases in 
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mortality attributable to infection. The results are HRs that 
can be used to predict reduction in deaths from avoided 
infections. The mean age of hospital patients will be used 
to predict years of life gained and preference-based utility 
scores will be used to weight life expectancy, allowing us to 
calculate QALYs. We will not collect primary data on pref-
erence-based utility scores. Instead, these estimates will be 
taken from the published literature.22
The change to total costs at the hospital level will be esti-
mated by summing intervention costs and deducting cost 
savings from reduced lengths of stay and use of healthcare 
resources that arise from reduced incidences of infection. 
The changes to health benefits will be estimated in QALYs 
using the number of life years saved from reduced infection 
outcomes; the expected duration of life (had infection not 
occurred) based on age and data from the published litera-
ture.17 All costs and health benefits arising in future periods 
will be appropriately discounted. Uncertainties in param-
eter estimates will be captured using appropriate statistical 
distributions to describe the variability. For example, the 
beta distribution would be a good choice for infection risk 
as this distribution is restricted to interval 0–1. The param-
eters of the beta distribution will be chosen to reflect what 
we know about the mean and range in infection risk (eg, 
a beta distribution with a mean rate of infection of 0.003% 
and 95% CI of 0.001 to 0.005). The fitted distributions will 
be subject to random re-samples simulated 10 000 times. The 
distributions of all prior parameters are used to estimate the 
posterior distributions of ‘change to costs’ and ‘change to 
QALY’ outcomes.
The decision will be informed by plotting cost-effective-
ness acceptability curves with threshold value between zero 
and 100 000 per QALY gained, and using the net monetary 
benefits framework.
These approaches are semi-Bayesian and appropriately 
account for all parameter uncertainty for the adoption 
decisions.
DIscussIon
This study addresses an identified gap in infection control 
research and practice. Despite the frequency of UTIs 
associated with indwelling urinary catheter use, there are 
few studies focusing on their surveillance and preven-
tion. Aligning with the emphasis on quality and safety, this 
multicentre randomised controlled trial will evaluate the 
effectiveness and cost-effectiveness of an antiseptic versus 
non-antiseptic meatal cleaning agent to prevent CAUTIs, a 
world first. The ultimate objective is the prevention of health-
care-related CAUTIs, leading to benefits for patient safety.
strengths
Few randomised controlled trials have investigated the 
effectiveness of antiseptics on CAUTI incidence during 
urinary catheter insertion, and previous research has been 
limited mainly due to the lack of an appropriate sample 
size to demonstrate any possible beneficial effect from the 
use of antiseptics.11 Our study uses a rigorous approach and 
is sufficiently powered to detect the effect of antiseptics in 
reducing CAUTI. The inclusion of the cost-effectiveness 
analysis is an additional strength of this trial as to our knowl-
edge previous trials have not evaluated the cost-effectiveness 
of an antiseptic meatal cleaning agent in reducing CAUTI. 
Over the past decade, cost-effectiveness analysis has evolved 
further emphasising the need to address this evidence gap.
This randomised controlled trial is also strengthened by 
the use of a stepped wedged design which has been found 
to be particularly useful in studies evaluating intervention 
effectiveness during routine implementation such as in the 
case of this study where the insertion of a urinary catheter is 
considered to be part of the care of the patient.23 The study 
design also enables each hospital to act as its own control, 
which removes the potential for some confounders such 
as variations in hospital size and case mix and differences 
between public and private hospitals. Furthermore, this 
study identifies best practice among current practice.
Limitations
Exclusion of patients who have indwelling urinary cath-
eters inserted in surgical theatre has the potential to 
prolong recruitment of participants given that surgical 
procedures are a common indication for urinary cath-
eter insertion.24 25 However, recruitment of these patients 
was not deemed feasible as it would require involvement 
of all surgeons including theatre staff in the study. Unless 
the participating hospital can achieve implementation in 
theatre, patients who have catheters inserted in theatres will 
be excluded. The initiatives taken to introduce the interven-
tion may inadvertently improve catheter management. To 
reduce this effect, no education on other aspects of cath-
eter management (other than the product change) will be 
provided to staff.
significance
It is important that urinary catheter insertion strategies for 
CAUTI prevention are supported by evidence obtained 
from rigorously conducted research. This study’s signifi-
cance therefore lies in its ability to inform recommenda-
tions within national infection control guidelines globally. 
This study will also contribute to the development of strat-
egies to reduce the incidence of CAUTI using cost-effective 
approaches. This is even more important in the context of 
finite health budgets.
trial status
The study team is completing the recruitment of partic-
ipating hospitals. The trial is due to commence in late 
2017.
Data quality
Data will be stored in electronically in a secure (password 
protected) location, by chief investigator BM at Avondale 
College of Higher Education. Data quality will be enhanced 
by the provision of adata collection form, quality checks by 
the project manager. A data collection guide has been  devel-
oped to aide and document this process. Data monitoring 
will be overseen by chief investigator BM and the data 
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monitoring committee consists of all chief investigators on 
the study. Any approved changes to the study protocol will 
be updated in Australia New Zealand Clinical  Trial Registry
Access to data
Chief investigator BM will hold data during and after 
study completion
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